PRODUCTS

PRODUCTS

position:Home > PRODUCTS > Pharmacogenomic Testing for Hypertension, Hyperlipidemia, Hyperglycemia and Hyperuricemia Disease Medications

Pharmacogenomic Testing for Hypertension, Hyperlipidemia, Hyperglycemia and Hyperuricemia Disease Medications

Contact Us

Product Introduction

Pharmacogenomic Testing for Hypertension, Hyperlipidemia, Hyperglycemia and Hyperuricemia Disease Medications, by detecting and analyzing the polymorphism of 57 genes related to 70 commonly used drugs for hypertension, hyperlipidemia, hyperglycemia and hyperuricemia, helps clinical drug use beyond the traditional framework of trial, observation and adjustment, guiding individualized medication in clinical practice, improving drug efficacy, helps determine appropriate dosage and reduces adverse drug reactions.

Product Features

High efficiency and accuracy

Authoritative guidance

Convenient operation

Applicable people

Patients taking hypertension, hyperlipidemia, hyperglycemia and hyperuricemia drugs for the first time.

Patients taking multiple medications simultaneously or for a long time.

Patients who have an unsatisfactory response to a certain drug.

Patients who have had adverse drug reactions themselves or among their family members.

Certain groups (those with impaired liver or kidney function, the elderly, children, etc.).

People who attach importance to safe medication.

Clinical significance

Individualized precision medicine

Provide reference for clinical rational drug use

Improve drug efficacy

Reduce adverse drug reactions

Detection Process

Informed consent

Sample collection

Nucleic acid extraction

Library preparation

Next generation sequencing

Data analysis

Reporting

Lead time

7 to 10 working days after receiving qualified samples.